RCKT•benzinga•
Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst
Summary
Chardan's Geulah Livshits raises target price for RCKT to $46 and maintains Buy rating after promising data on gene therapy for heart disease.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 16, 2025 by benzinga